BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM

KYOTO, Japan – July 26, 2011 BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM present data On LONG-LASTING RECOMBINANT factor VIII therapy at international society on thrombosis and haemostasis meeting —Results Show Potential to Significantly Reduce the Burden of Treatment forPeople with Hemophilia A— Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) today announced Phase 1/2a trial data […]